These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21045690)

  • 61. Mutant p53 as an Antigen in Cancer Immunotherapy.
    Sobhani N; D'Angelo A; Wang X; Young KH; Generali D; Li Y
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Non-disruptive mutation in
    Huang M; Jin J; Zhang F; Wu Y; Xu C; Ying L; Su D
    Ann Transl Med; 2020 Mar; 8(6):316. PubMed ID: 32355760
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.
    Gupta I; Sareyeldin RM; Al-Hashimi I; Al-Thawadi HA; Al Farsi H; Vranic S; Al Moustafa AE
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30871273
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.
    Arbitrio M; Di Martino MT; Scionti F; Barbieri V; Pensabene L; Tagliaferri P
    High Throughput; 2018 Dec; 7(4):. PubMed ID: 30567415
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Multifaceted Metabolism of Glioblastoma.
    Quinones A; Le A
    Adv Exp Med Biol; 2018; 1063():59-72. PubMed ID: 29946775
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NetNorM: Capturing cancer-relevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis.
    Le Morvan M; Zinovyev A; Vert JP
    PLoS Comput Biol; 2017 Jun; 13(6):e1005573. PubMed ID: 28650955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Network based stratification of major cancers by integrating somatic mutation and gene expression data.
    He Z; Zhang J; Yuan X; Liu Z; Liu B; Tuo S; Liu Y
    PLoS One; 2017; 12(5):e0177662. PubMed ID: 28520777
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network.
    Yang L; Wang S; Zhou M; Chen X; Jiang W; Zuo Y; Lv Y
    Sci Rep; 2017 Apr; 7(1):738. PubMed ID: 28389666
    [TBL] [Abstract][Full Text] [Related]  

  • 69. p53 mutations promote proteasomal activity.
    Oren M; Kotler E
    Nat Cell Biol; 2016 Jul; 18(8):833-5. PubMed ID: 27463250
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.
    Halvorsen AR; Silwal-Pandit L; Meza-Zepeda LA; Vodak D; Vu P; Sagerup C; Hovig E; Myklebost O; Børresen-Dale AL; Brustugun OT; Helland Å
    Front Genet; 2016; 7():85. PubMed ID: 27242894
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis.
    Fisher OM; Lord SJ; Falkenback D; Clemons NJ; Eslick GD; Lord RV
    Gut; 2017 Mar; 66(3):399-410. PubMed ID: 26733670
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes.
    Zhong X; Yang H; Zhao S; Shyr Y; Li B
    BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S7. PubMed ID: 26099277
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aneuploidy and chromosomal instability in cancer: a jackpot to chaos.
    Giam M; Rancati G
    Cell Div; 2015; 10():3. PubMed ID: 26015801
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unravelling mechanisms of p53-mediated tumour suppression.
    Bieging KT; Mello SS; Attardi LD
    Nat Rev Cancer; 2014 May; 14(5):359-70. PubMed ID: 24739573
    [TBL] [Abstract][Full Text] [Related]  

  • 75. How to get the most from microarray data: advice from reverse genomics.
    Gorlov IP; Yang JY; Byun J; Logothetis C; Gorlova OY; Do KA; Amos C
    BMC Genomics; 2014 Mar; 15():223. PubMed ID: 24656147
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High frequency of temperature-sensitive mutants of p53 in glioblastoma.
    Smardova J; Liskova K; Ravcukova B; Kubiczkova L; Sevcikova S; Michalek J; Svitakova M; Vybihal V; Kren L; Smarda J
    Pathol Oncol Res; 2013 Jul; 19(3):421-8. PubMed ID: 23536279
    [TBL] [Abstract][Full Text] [Related]  

  • 77. p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
    Chen L; Tweddle DA
    Front Oncol; 2012; 2():173. PubMed ID: 23226679
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.
    Drake JM; Graham NA; Stoyanova T; Sedghi A; Goldstein AS; Cai H; Smith DA; Zhang H; Komisopoulou E; Huang J; Graeber TG; Witte ON
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1643-8. PubMed ID: 22307624
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clonal evolution in cancer.
    Greaves M; Maley CC
    Nature; 2012 Jan; 481(7381):306-13. PubMed ID: 22258609
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.
    Olivier M; Taniere P
    Curr Opin Oncol; 2011 Jan; 23(1):88-92. PubMed ID: 21045690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.